A major role for the minor capsid protein of human papillomavirus type 16 in immune escape

Journal of Immunology

Volumn 183, Issue 10, 2009, Pages 6151-6156

  Fahey, Laura M ^a   Raff, Adam B ^b   Da Silva, Diane M ^a,c   Kast, W Martin ^a,c,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; CAPSID PROTEIN L2; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVATION; CELL MATURATION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOMODULATION; LANGERHANS CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; UTERINE CERVIX CANCER; UTERINE CERVIX EPITHELIUM; VIRUS LIKE AGENT;

CAPSID PROTEINS; CELL MOVEMENT; CYTOKINES; DENDRITIC CELLS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; LANGERHANS CELLS; LIPOPOLYSACCHARIDES; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 77954230704     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902145     Document Type: Article

References (32)

1. Parkin, D. M. 2006. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118: 3030-3044.
2. Walboomers, J. M., V. Jacobs, M. M. Manos, F. X. Bosch, J. A. Kummer, K. V. Shah, P. J. Snijders, J. Peto, C. J. Meijer, and N. Munoz. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 182: 12-19.
3. Syrjänen, K., M. Hakama, S. Saarikoski, M. Väyrynen, M. Yliskoski, S. Syrjänen, V. Kataja, and O. Castrén. 1990. Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a nonselected Finnish female population. Sex Trans. Dis. 17: 15-19. (Pubitemid 20110405)
4. Woodman, C. B., S. Collins, H. Winter, A. Bailey, J. Ellis, P. Prior, M. Yates, T. P. Rollason, and L. S. Young. 2001. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 9: 1831-1836.
5. Stanley, M. A., M. R. Pett, and N. Coleman. 2007. HPV: from infection to cancer. Biochem. Soc. Trans. 35: 1456-1460.
6. Kirnbauer, R., F. Booy, N. Cheng, D. R. Lowy, and J. T Schiller. 1992. Papillomavirus L1 major capsid protein self-assemble into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA 89: 12180-12184.
7. Kirnbauer, R., J. Taub, H. Greenstone, R. Roden, M. Durst, L. Gissmann, D. R. Lowy, and J. T. Schiller. 1993. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol. 67: 6929-6939.
8. Buck, C. B., N. Cheng, C. D. Thompson, D. R. Lowy, A. C. Steven, J. T. Schiller, and B. L. Trus. 2008. Arrangement of L2 within the papillomavirus capsid. J. Virol. 82: 5190-5197.
9. Finnen, R. L., K. D. Erickson, X. S. Chen, and R. L. Garcea. 2003. Interactions between papillomavirus L1 and L2 capsid proteins. J. Virol. 77: 4818-4826.
10. Zhao, K. N., X. Y. Sun, I. H. Frazer, and J. Zhou. 1998. DNA packaging by L1 and L2 capsid proteins of bovine papillomavirus type 1. Virology 243: 482-491.
11. Kawana, Y., K. Kawana, H. Yoshikawa, Y. Taketani, K. Yoshiike, and T. Kanda. 2001. Human papillomavirus type 16 minor capsid protein L2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm. J. Virol. 75: 2331-2336.
12. Yang, R., P. M. Day, W. H. Yutzy, 4th, K. Lin, C. Hung, and R. B. S. Roden. 2003. Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J. Virol. 77: 3531-3541.
13. Yang, R., W. H. Yutzy, 4th, R. P. Viscidi, and R. B. S. Roden. 2003. Interaction of L2 with β-actin directs intracellular transport of papillomavirus and infection. J. Biol. Chem. 278: 12546-12553.
14. Kämper, N., P. M. Day, T. Nowak, H. C. Selinka, L. Florin, J. Bolscher, L. Hilbig, J. T. Schiller, and M. Sapp. 2006. A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes. J. Virol. 80: 759-768.
15. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392: 245-252.
16. Lenz, P., P. M. Day, Y. S. Pang, S. A. Frye, P. N. Jensen, D. R. Lowy, and J. T. Schiller. 2001. Papillomavirus-like particles induce acute activation of dendritic cells. J. Immunol. 166: 5346-5355. (Pubitemid 32374153)
17. Rudolf, M., S. C. Fausch, D. M. Da Silva, and W. M Kast. 2001. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J. Immunol. 166: 5917-5924. (Pubitemid 32440715)
18. de Witte, L., Y. Zoughlami, B. Aengeneyndt, G. David, Y. van Kooyk, L. Gissmann, and T. B. Geijtenbeek. 2008. Binding of human papillomavirus L1 virus-like particles to dendritic cells is mediated through heparan sulfates and induces immune activation. Immunobiology 212: 679-691.
19. Fausch, S. C., D. M. Da Silva, M. P. Rudolf, and W. M. Kast. 2002. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J. Immunol. 169: 3242-3249.
20. Fausch, S. C., L. M. Fahey, D. M. Da Silva, and W. M. Kast. 2005. HPV can escape immune recognition through Langerhans cell PI3-kinase activation. J. Immunol. 174: 7172-7178.
21. Yan, M., J. Peng, I. A. Jabbar, X. Liu, L. Filgueira, I. H. Frazer, and R. Thomas. 2004. Despite differences between dendritic cells and Langerhans cells in the mechanism of papillomavirus-like particle antigen uptake, both cells cross-prime T cells. Virology 324: 297-310.
22. Bousarghin, L., P. Hubert, E. Franzen, N. Jacobs, and P. Delvenne. 2005. Human papillomavirus 16 virus-like particles use heparan sulfates to bind dendritic cells and colocalize with langerin in Langerhans cells. J. Gen. Virol. 86: 1297-1305.
23. Fausch, S. C., D. M. Da Silva, and W. M. Kast. 2003. Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res. 63: 3478-3482.
24. Fahey, L. M., A. B. Raff, D. M. Da Silva, and W. M. Kast. 2009. Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. J. Immunol. 182: 2919-2928.
25. Kaufmann, A. M., J. Nieland, M. Schinz, M. Nonn, J. Gabelsberger, H. Meissner, R. T. Müller, I. Jochmus, L. Gissmann, A. Schneider, and M. Dürst. 2001. HPV16L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. Int. J. Cancer 92: 285-293.
26. + dermal dendritic cells. Immunity 29: 497-510.
27. Saeki, H., A. M. Moore, M. J. Brown, and S. T. Hwang. 1999. Secondary lymphoid tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. J. Immunol. 162: 2472-2475.
28. Kanodia, S., L. M. Fahey, and W. M. Kast. 2007. Mechanisms used by human papillomavirus to escape the host immune response. Curr. Cancer Drug Targets 7: 79-89.
29. Schlecht, N. F., S. Kulaga, J. Robitaille, S. Ferreira, M. Santos, R. A. Miyamura, E. Duarte-Franco, T. E. Rohan, A. Ferenczy, L. L. Villa, and E. L. Franco. 2001. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. J. Am. Med. Assoc. 286: 3106-3114.
30. Gambhira, R., B. Karanam, S. Jagu, J. N. Roberts, C. B. Buck, I. Bossis, H. Alphs, T. Culp, N. D. Christensen, and R. B. Roden. 2007. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J. Virol. 81: 13927-13931.
31. Tan, P., C. Anasetti, J. A. Hansen, J. Melrose, M. Brunvand, J. Bradshaw, J. A. Ledbetter, and P. S. Linsley. 1993. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interactions of CD28 with its natural ligand B7/BB1. J. Exp. Med. 177: 165-173.
32. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192: 1213-1222.